Leerink Partners analyst Puneet Souda maintained a Buy rating on NeoGenomics (NEO – Research Report) on April 18. The company’s shares closed last Friday at $13.53.
According to TipRanks, Souda is an analyst with an average return of -11.2% and a 34.08% success rate. Souda covers the Healthcare sector, focusing on stocks such as Natera, Quanterix, and Bruker.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for NeoGenomics with a $20.43 average price target.
The company has a one-year high of $21.22 and a one-year low of $11.03. Currently, NeoGenomics has an average volume of 902.7K.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NEO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NeoGenomics (NEO) Company Description:
NeoGenomics, Inc. is a clinical laboratory, which specializes in cancer genetics diagnostic testing and pharma services. It operates through the following two segments: Clinical and Pharma Services. The Clinical Services segment offers clinical cancer testing services to community-based pathologists. The Pharma Services segments supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. The Clinical Services Segment provides various clinical testing services to community-based pathology practices, hospital pathology labs and academic centers with reimbursement from various payers including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment: provides comprehensive testing services in supports pharmaceutical clients’ oncology programs from discovery to commercialization. Its services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology and molecular genetic testing. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
